Compare Progressive Corp (PGR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Zoetis Inc — how do they compare? Progressive Corp trades at $217.43 (market cap $126.95B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Progressive Corp is far larger — about 4.2× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Zoetis Inc for 70 Days on average.
| PGR | ZTS | |
|---|---|---|
Market Cap | $126.95B | $30.20B |
Volume | 2,749,438 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $240.40 | $147.53 |
52-Week Low | $190.40 | $69.09 |
Typical Hold Time | 81 Days | 70 Days |
Enterprise Value | $135.16B | $37.76B |
Dividend Yield | 0.18% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $218.73, up 2.15% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $87.64B and net income of $11.31B, supported by consistent earnings beats and a 12.85% net margin. Analyst consensus sits at $222.23 with 38% buy ratings, while technical indicators show support at $216 and resistance at $221.
PGR presents a favorable risk-reward profile with solid profitability and growth trajectory, though competitive pressures in auto insurance and potential market volatility warrant caution. The stock's current valuation metrics (P/E 10.97, P/S 1.41) appear reasonable relative to earnings power, supporting a constructive outlook for long-term investors.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
